You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimethoprim
Accession NumberDB00440  (APRD00103)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim resistance has been reported. [PubChem]
Structure
Thumb
Synonyms
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
Proloprim
Trimethoprim
Triméthoprime
Trimethoprimum
Trimetoprima
Trimpex
External Identifiers
  • BW 56-72
  • Ro 6-2153-12 F
  • UNII-9XE000OU9B
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrimsolSolution50 mg/5mLOralFSC Laboratories, Inc2000-01-24Not applicableUs
PrimsolSolution50 mg/5mLOralAytu Bio Science, Inc.2015-09-15Not applicableUs
Proloprim 200 Tab 200mgTablet200 mgOralGlaxosmithkline Inc1985-12-312004-08-05Canada
Proloprim Tab 100mgTablet100 mgOralGlaxosmithkline Inc1986-12-312003-10-28Canada
TrimethoprimTablet100 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
TrimethoprimTablet100 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-302017-12-31Us
Trimethoprim TabletsTablet100 mgOralAa Pharma Inc2001-01-01Not applicableCanada
Trimethoprim TabletsTablet200 mgOralAa Pharma Inc2001-07-30Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrimethoprimTablet100 mg/1OralCarilion Materials Management2010-04-04Not applicableUs
TrimethoprimTablet100 mg/1OralWatson Laboratories, Inc.2010-04-04Not applicableUs
TrimethoprimTablet100 mg/1OralAv Pak2013-07-31Not applicableUs
TrimethoprimTablet100 mg/1OralNovel Laboratories, Inc.2011-06-24Not applicableUs
TrimethoprimTablet100 mg/1OralREMEDYREPACK INC.2013-09-24Not applicableUs
TrimethoprimTablet100 mg/1OralAv Kare, Inc.2013-05-06Not applicableUs
TrimethoprimTablet100 mg/1OralPhysicians Total Care, Inc.2012-05-02Not applicableUs
TrimethoprimTablet100 mg/1OralGAVIS Pharmaceuticals, LLC2011-06-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlprimAlphapharm
CatinKojar
EumiHwang's
InflamnilSwiss Pharm
LannacherRoot
LariagoIpca Laboratories
MeprimJohnson
MetipineKojar
MonotrimGlaxoSmithKline
MotrimLannacher
ProloprimGlaxoSmithKline
TrimpexNot Available
TriprimGlaxoSmithKline
Brand mixtures
NameLabellerIngredients
Apo Sulfatrim DS TabApotex Inc
Apo Sulfatrim PediatricApotex Inc
Apo Sulfatrim TabApotex Inc
Apo-sulfatrim Oral SuspensionApotex Inc
BactrimAR Scientific, Inc.
Bactrim DSAR Scientific, Inc.
Bactrim DS Roche TabHoffmann La Roche Limited
Bactrim Roche InjHoffmann La Roche Limited
Bactrim Roche Suspension PaediatricHoffmann La Roche Limited
Bactrim Roche TabHoffmann La Roche Limited
Coptin Oral SuspensionAxcan Pharma Inc
Coptin TabPfizer Canada Inc
Nu-cotrimox Sus 40/8mg/mlNu Pharm Inc
Nu-cotrimox Tab 400/80mgNu Pharm Inc
Nu-cotrimox-DS Tab 800/160mgNu Pharm Inc
PMS-polytrimethoprimPharmascience Inc
Polymyxin B Sulfate and TrimethoprimSTAT RX LLC USA
Polymyxin B Sulfate and Trimethoprim SulfateMedsource Pharmaceuticals
PolytrimAllergan, Inc.
Polytrim Ophthalmic SolutionAllergan Inc
Protrin Df TabPro Doc Limitee
Protrin TabPro Doc Limitee
Riva-sep DSLaboratoire Riva Inc
Roubac Tab 160/800Rougier Pharma Division Of Ratiopharm Inc
Roubac Tab 80/400Rougier Pharma Division Of Ratiopharm Inc
Sandoz PolytrimethoprimSandoz Canada Incorporated
SeptraGlaxosmithkline Inc
Septra DS TabletsGlaxosmithkline Inc
Septra InjectionAspen Pharma Trading Limited
Septra Pediatric SuspensionGlaxosmithkline Inc
Sulfamethoxazole and TrimethoprimTeva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim (double Strength)Teva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim Double StrengthLake Erie Medical Dba Quality L Care Products Lc
Sulfamethoxazole and Trimethoprim DSApotheca Inc.
Sulfamethoxazole and Trimethoprim TabletsD.C. Labs Limited
SulfatrimSTI Pharma LLC
Teva-trimelTeva Canada Limited
Teva-trimel DSTeva Canada Limited
Trimethoprim Sulfate and Polymyxin B SulfateAkorn, Inc.
Trisulfa DS TabJaapharm Canada Inc.
Trisulfa S SuspensionJaapharm Canada Inc.
Trisulfa TabJaapharm Canada Inc.
Salts
Name/CASStructureProperties
Trimethoprim hydrochloride
ThumbNot applicableDBSALT001480
Trimethoprim sulfate
ThumbNot applicableDBSALT001471
Categories
UNIIAN164J8Y0X
CAS number738-70-5
WeightAverage: 290.3177
Monoisotopic: 290.137890462
Chemical FormulaC14H18N4O3
InChI KeyIEDVJHCEMCRBQM-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
IUPAC Name
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
SMILES
COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
Pharmacology
IndicationFor the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.
Structured Indications
PharmacodynamicsTrimethoprim is a pyrimidine analogue that disrupts folate synthesis, an essential part of the thymidine synthesis pathway. Inhibition of the enzyme starves the bacteria of nucleotides necessary for DNA replication.The drug, therefore, exhibits bactericidal activity.
Mechanism of actionTrimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF). THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis. Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase. Sulfamethoxazole inhibits dihydrofolate synthetase (aka dihydropteroate synthetase), an enzyme involved further upstream in the same pathway. Trimethoprim and sulfamethoxazole are commonly used in combination due to their synergistic effects. This drug combination also reduces the development of resistance that is seen when either drug is used alone.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thymidylate synthaseProteinyes
inhibitor
HumanP04818 details
Dihydrofolate reductaseProteinno
inhibitor
HumanP00374 details
Related Articles
AbsorptionReadily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF.
Volume of distributionNot Available
Protein binding42-46% bound to plasma proteins
Metabolism

Hepatic metabolism to oxide and hydroxylated metabolites.

Route of eliminationTen to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim. Trimethoprim also passes the placental barrier and is excreted in human milk.
Half life8-11 hours in adults with normal renal function
ClearanceNot Available
ToxicityLD50=4850 (orally in mice)
Affected organisms
  • Gram negative and gram positive bacteria
  • Listeria monocytogenes
  • Escherichia coli
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Trimethoprim can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Trimethoprim.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Trimethoprim.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Trimethoprim.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Trimethoprim.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Trimethoprim.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Trimethoprim.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Trimethoprim.Experimental
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Trimethoprim.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Trimethoprim.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Trimethoprim.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Trimethoprim.Approved, Illicit, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Trimethoprim.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Trimethoprim.Approved, Withdrawn
AmiodaroneThe metabolism of Trimethoprim can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Trimethoprim.Approved
AmodiaquineTrimethoprim may increase the neutropenic activities of Amodiaquine.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Trimethoprim.Approved
AnagrelideTrimethoprim may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Trimethoprim.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Trimethoprim.Approved
AprepitantThe serum concentration of Trimethoprim can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Trimethoprim.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Trimethoprim.Approved, Investigational
Arsenic trioxideTrimethoprim may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Trimethoprim.Approved
AsenapineTrimethoprim may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Trimethoprim can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Trimethoprim.Approved
AtomoxetineThe metabolism of Trimethoprim can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Trimethoprim.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Trimethoprim.Approved, Investigational
AzathioprineTrimethoprim may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Trimethoprim.Approved
Azilsartan medoxomilTrimethoprim may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
AzithromycinTrimethoprim may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineTrimethoprim may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilTrimethoprim may increase the hyperkalemic activities of Benazepril.Approved, Investigational
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Trimethoprim.Approved
BeraprostThe metabolism of Beraprost can be decreased when combined with Trimethoprim.Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
BexaroteneThe serum concentration of Trimethoprim can be decreased when it is combined with Bexarotene.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Trimethoprim.Investigational
BoceprevirThe metabolism of Trimethoprim can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Trimethoprim can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Trimethoprim.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trimethoprim.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trimethoprim.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Trimethoprim.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Trimethoprim.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Trimethoprim.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Trimethoprim.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Trimethoprim.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Trimethoprim.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Trimethoprim.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Trimethoprim.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Trimethoprim.Approved
CandesartanTrimethoprim may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilTrimethoprim may increase the hyperkalemic activities of Candoxatril.Experimental
CapecitabineThe metabolism of Trimethoprim can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilTrimethoprim may increase the hyperkalemic activities of Captopril.Approved
CarbamazepineThe metabolism of Trimethoprim can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Trimethoprim.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Trimethoprim.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Trimethoprim.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Trimethoprim.Approved, Investigational
CeritinibThe serum concentration of Trimethoprim can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Trimethoprim.Withdrawn
ChloroquineTrimethoprim may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Trimethoprim.Approved
CholecalciferolThe metabolism of Trimethoprim can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilTrimethoprim may increase the hyperkalemic activities of Cilazapril.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Trimethoprim.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Trimethoprim.Approved
CiprofloxacinTrimethoprim may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTrimethoprim may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Trimethoprim.Approved
CitalopramTrimethoprim may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Trimethoprim can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trimethoprim can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Trimethoprim.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Trimethoprim.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Trimethoprim.Approved
ClopidogrelThe metabolism of Trimethoprim can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Trimethoprim can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTrimethoprim may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Trimethoprim can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Trimethoprim.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trimethoprim.Approved
ConivaptanThe serum concentration of Trimethoprim can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trimethoprim.Approved
CrizotinibTrimethoprim may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.Approved, Investigational
CyclosporineThe metabolism of Trimethoprim can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.Approved
DabrafenibThe serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Trimethoprim.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Trimethoprim.Approved
DapsoneThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Dapsone.Approved, Investigational
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Trimethoprim.Approved, Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Trimethoprim.Approved, Investigational
DarunavirThe metabolism of Trimethoprim can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Trimethoprim.Approved
DasatinibThe serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Trimethoprim.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Trimethoprim.Approved
DeferasiroxThe serum concentration of Trimethoprim can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Trimethoprim can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Trimethoprim can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Trimethoprim.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Trimethoprim.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Trimethoprim.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Trimethoprim.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trimethoprim.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Trimethoprim.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trimethoprim.Approved
DihydroergotamineThe metabolism of Trimethoprim can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Trimethoprim.Illicit
DiltiazemThe metabolism of Trimethoprim can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Trimethoprim.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Trimethoprim.Approved
DisopyramideTrimethoprim may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Trimethoprim.Approved, Investigational
DofetilideTrimethoprim may decrease the excretion rate of Dofetilide which could result in a higher serum level.Approved
DolasetronTrimethoprim may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTrimethoprim may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Trimethoprim.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Trimethoprim.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Trimethoprim.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Trimethoprim.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trimethoprim.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Trimethoprim.Approved, Investigational
DoxycyclineThe metabolism of Trimethoprim can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Trimethoprim.Approved, Illicit
DronedaroneTrimethoprim may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolTrimethoprim may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trimethoprim.Approved
EfavirenzThe serum concentration of Trimethoprim can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Trimethoprim.Approved, Investigational
EliglustatTrimethoprim may increase the QTc-prolonging activities of Eliglustat.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Trimethoprim.Approved
EnalaprilTrimethoprim may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatTrimethoprim may increase the hyperkalemic activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Trimethoprim.Approved, Investigational
EplerenoneTrimethoprim may increase the hyperkalemic activities of Eplerenone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Trimethoprim.Approved
EprosartanTrimethoprim may increase the hyperkalemic activities of Eprosartan.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Trimethoprim.Approved, Investigational
ErythromycinTrimethoprim may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTrimethoprim may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Trimethoprim can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trimethoprim.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Trimethoprim.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Trimethoprim.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trimethoprim.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Trimethoprim.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Trimethoprim.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Trimethoprim.Approved, Investigational
EtravirineThe serum concentration of Trimethoprim can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trimethoprim.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Trimethoprim.Approved
FelodipineThe metabolism of Trimethoprim can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Trimethoprim.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Trimethoprim.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Trimethoprim.Approved
FlecainideTrimethoprim may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloxuridineThe metabolism of Trimethoprim can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Trimethoprim can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Trimethoprim.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Trimethoprim.Approved, Illicit
FluorouracilThe metabolism of Trimethoprim can be decreased when combined with Fluorouracil.Approved
FluoxetineTrimethoprim may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTrimethoprim may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Trimethoprim.Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Trimethoprim.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trimethoprim.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Trimethoprim.Approved
FluvoxamineThe metabolism of Trimethoprim can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanTrimethoprim may increase the hyperkalemic activities of Forasartan.Experimental
FormoterolThe metabolism of Formoterol can be decreased when combined with Trimethoprim.Approved, Investigational
FosamprenavirThe metabolism of Trimethoprim can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trimethoprim can be increased when it is combined with Fosaprepitant.Approved
FosinoprilTrimethoprim may increase the hyperkalemic activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Trimethoprim can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Trimethoprim can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidTrimethoprim may increase the QTc-prolonging activities of Gadobenic acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Trimethoprim.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Trimethoprim.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Trimethoprim.Approved
GemfibrozilThe metabolism of Trimethoprim can be decreased when combined with Gemfibrozil.Approved
GemifloxacinTrimethoprim may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Trimethoprim.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Trimethoprim.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Trimethoprim.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Trimethoprim.Approved
GoserelinTrimethoprim may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTrimethoprim may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Trimethoprim.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Trimethoprim.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Trimethoprim.Approved
HaloperidolTrimethoprim may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Trimethoprim.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Trimethoprim.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Trimethoprim.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Trimethoprim.Approved, Illicit
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Trimethoprim.Approved
IbutilideTrimethoprim may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Trimethoprim.Approved
IdelalisibThe serum concentration of Trimethoprim can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Trimethoprim.Approved
IloperidoneTrimethoprim may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Trimethoprim can be decreased when combined with Imatinib.Approved
ImidaprilTrimethoprim may increase the hyperkalemic activities of Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Trimethoprim.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Trimethoprim.Approved
IndinavirThe metabolism of Trimethoprim can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Trimethoprim.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Trimethoprim.Approved, Investigational
IrbesartanTrimethoprim may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Trimethoprim.Approved, Investigational
IsavuconazoniumThe metabolism of Trimethoprim can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Trimethoprim can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Trimethoprim can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trimethoprim can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Trimethoprim.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Trimethoprim.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Trimethoprim.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Trimethoprim.Approved
KetoconazoleThe metabolism of Trimethoprim can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
LamivudineTrimethoprim may decrease the excretion rate of Lamivudine which could result in a higher serum level.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Trimethoprim.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Trimethoprim.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Trimethoprim.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Trimethoprim.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Trimethoprim.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Trimethoprim.Approved
LenvatinibTrimethoprim may increase the QTc-prolonging activities of Lenvatinib.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Trimethoprim.Approved
LeuprolideTrimethoprim may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Trimethoprim.Approved, Investigational
LevofloxacinTrimethoprim may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Trimethoprim.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Trimethoprim.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Trimethoprim.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Trimethoprim.Approved
LisinoprilTrimethoprim may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Trimethoprim.Approved
LopinavirThe metabolism of Trimethoprim can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Trimethoprim.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Trimethoprim.Approved
LosartanTrimethoprim may increase the hyperkalemic activities of Losartan.Approved
LovastatinThe metabolism of Trimethoprim can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Trimethoprim can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Trimethoprim can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Trimethoprim.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Trimethoprim.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Trimethoprim.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Trimethoprim.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Memantine.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Trimethoprim.Investigational, Withdrawn
MercaptopurineTrimethoprim may increase the myelosuppressive activities of Mercaptopurine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Trimethoprim.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Trimethoprim.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Trimethoprim.Approved
MethadoneTrimethoprim may increase the QTc-prolonging activities of Methadone.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Trimethoprim.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Trimethoprim.Approved, Vet Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Trimethoprim.Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Trimethoprim.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Trimethoprim.Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.Approved, Illicit
MifepristoneThe serum concentration of Trimethoprim can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Trimethoprim.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Trimethoprim.Approved
MitotaneThe serum concentration of Trimethoprim can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Trimethoprim.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Trimethoprim.Approved
ModafinilThe serum concentration of Trimethoprim can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilTrimethoprim may increase the hyperkalemic activities of Moexipril.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Trimethoprim.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Trimethoprim.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be decreased when it is combined with Trimethoprim.Approved, Investigational
MoxifloxacinTrimethoprim may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Trimethoprim.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trimethoprim.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Trimethoprim.Approved
NafcillinThe serum concentration of Trimethoprim can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trimethoprim.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Trimethoprim.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Trimethoprim.Approved, Investigational
NefazodoneThe metabolism of Trimethoprim can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Trimethoprim can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trimethoprim can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Trimethoprim can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Trimethoprim can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Trimethoprim.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Trimethoprim.Approved
NilotinibTrimethoprim may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Trimethoprim.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Trimethoprim.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Trimethoprim.Approved
OfloxacinTrimethoprim may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Trimethoprim.Approved, Investigational
OlaparibThe metabolism of Trimethoprim can be decreased when combined with Olaparib.Approved
OlmesartanTrimethoprim may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Trimethoprim.Approved
OmapatrilatTrimethoprim may increase the hyperkalemic activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Trimethoprim.Approved
OmeprazoleThe metabolism of Trimethoprim can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronTrimethoprim may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Trimethoprim can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Trimethoprim.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Trimethoprim.Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
PalbociclibThe serum concentration of Trimethoprim can be increased when it is combined with Palbociclib.Approved
PaliperidoneTrimethoprim may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTrimethoprim may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Trimethoprim.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Trimethoprim.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.Approved
PentamidineTrimethoprim may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Trimethoprim can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Trimethoprim.Investigational
PerflutrenTrimethoprim may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilTrimethoprim may increase the hyperkalemic activities of Perindopril.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Trimethoprim.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Trimethoprim.Withdrawn
PhenobarbitalThe metabolism of Trimethoprim can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Trimethoprim.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Trimethoprim.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
PimozideTrimethoprim may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Trimethoprim.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Trimethoprim.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Trimethoprim.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Trimethoprim.Approved
PosaconazoleThe metabolism of Trimethoprim can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trimethoprim.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Trimethoprim.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Trimethoprim.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Trimethoprim.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
PrimaquineTrimethoprim may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Trimethoprim can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe serum concentration of the active metabolites of Procainamide can be increased when Procainamide is used in combination with Trimethoprim.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Trimethoprim.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Trimethoprim.Approved
PropafenoneTrimethoprim may increase the QTc-prolonging activities of Propafenone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Trimethoprim.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Trimethoprim.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Trimethoprim.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trimethoprim.Approved
PyrimethamineThe metabolism of Trimethoprim can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Trimethoprim.Approved, Illicit
QuetiapineTrimethoprim may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilTrimethoprim may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinidineTrimethoprim may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTrimethoprim may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Trimethoprim can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilTrimethoprim may increase the hyperkalemic activities of Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Trimethoprim.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trimethoprim.Approved, Investigational
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Trimethoprim.Approved, Investigational
RescinnamineTrimethoprim may increase the hyperkalemic activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Trimethoprim.Approved
RifabutinThe metabolism of Trimethoprim can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Trimethoprim can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trimethoprim can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trimethoprim.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Trimethoprim.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Trimethoprim.Approved, Investigational
RitonavirThe metabolism of Trimethoprim can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Trimethoprim.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Trimethoprim.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Trimethoprim.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Trimethoprim.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Trimethoprim.Approved
SacubitrilTrimethoprim may increase the hyperkalemic activities of Sacubitril.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
SaprisartanTrimethoprim may increase the hyperkalemic activities of Saprisartan.Experimental
SaquinavirThe metabolism of Trimethoprim can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinTrimethoprim may increase the hyperkalemic activities of Saralasin.Investigational
SecobarbitalThe metabolism of Trimethoprim can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Trimethoprim.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Trimethoprim.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Trimethoprim.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Trimethoprim.Approved
SildenafilThe metabolism of Trimethoprim can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trimethoprim.Approved
SiltuximabThe serum concentration of Trimethoprim can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Trimethoprim can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Trimethoprim.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Trimethoprim.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Trimethoprim.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Trimethoprim.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Trimethoprim.Approved, Investigational
SotalolTrimethoprim may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Trimethoprim.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Trimethoprim.Experimental
SpiraprilTrimethoprim may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneTrimethoprim may increase the hyperkalemic activities of Spironolactone.Approved
St. John's WortThe serum concentration of Trimethoprim can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Trimethoprim can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Trimethoprim can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Trimethoprim.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Trimethoprim.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Trimethoprim.Approved
SulfisoxazoleThe metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Trimethoprim.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Trimethoprim.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Trimethoprim.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Trimethoprim.Approved
TasosartanTrimethoprim may increase the hyperkalemic activities of Tasosartan.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trimethoprim.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Trimethoprim.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Trimethoprim.Approved
TelaprevirThe metabolism of Trimethoprim can be decreased when combined with Telaprevir.Approved
TelavancinTrimethoprim may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Trimethoprim can be decreased when combined with Telithromycin.Approved
TelmisartanTrimethoprim may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Trimethoprim.Approved
TemocaprilTrimethoprim may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Trimethoprim.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Trimethoprim.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Trimethoprim.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Trimethoprim.Withdrawn
TeriflunomideThe metabolism of Trimethoprim can be decreased when combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Trimethoprim.Approved, Investigational
TetrabenazineTrimethoprim may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Trimethoprim.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Trimethoprim.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Trimethoprim.Approved, Vet Approved
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Trimethoprim.Withdrawn
ThioridazineTrimethoprim may increase the QTc-prolonging activities of Thioridazine.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Trimethoprim.Approved
TiclopidineThe metabolism of Trimethoprim can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Trimethoprim.Approved
TocilizumabThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Trimethoprim can be decreased when combined with Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Trimethoprim.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Trimethoprim.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trimethoprim.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Trimethoprim.Approved
ToremifeneTrimethoprim may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Trimethoprim.Approved, Investigational
TrandolaprilTrimethoprim may increase the hyperkalemic activities of Trandolapril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trimethoprim.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Trimethoprim.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Trimethoprim.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Trimethoprim.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Trimethoprim.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Trimethoprim.Withdrawn
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Trimethoprim.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Trimethoprim.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Trimethoprim.Investigational, Withdrawn
Valproic AcidThe metabolism of Trimethoprim can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanTrimethoprim may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VandetanibTrimethoprim may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Trimethoprim.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Trimethoprim.Approved
VemurafenibTrimethoprim may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Trimethoprim.Approved
VenlafaxineThe metabolism of Trimethoprim can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Trimethoprim can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Trimethoprim.Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Trimethoprim.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Trimethoprim.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Trimethoprim.Approved
VoriconazoleThe metabolism of Trimethoprim can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Trimethoprim.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Trimethoprim.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Trimethoprim.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Trimethoprim.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Trimethoprim.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Trimethoprim.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trimethoprim.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Trimethoprim.Approved, Investigational, Withdrawn
ZiprasidoneTrimethoprim may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Trimethoprim.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Trimethoprim.Approved
ZuclopenthixolTrimethoprim may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.
References
Synthesis Reference

Yasushi Takagishi, Kiichiro Ohsuga, Sadao Ohama, “Suppository containing sulfamethoxazole/trimethoprim complex and process for preparing the same.” U.S. Patent US4461765, issued December, 1975.

US4461765
General References
  1. Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. [PubMed:8195839 ]
  2. Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. [PubMed:8071675 ]
  3. Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. [PubMed:16150859 ]
  4. Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. [PubMed:12239226 ]
  5. Johnson JR, Manges AR, O'Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. [PubMed:12103291 ]
External Links
ATC CodesJ01EE07J01EE01J01EE05J01EA01J01EE04J01EE02J01EE03
AHFS Codes
  • 08:36.00
PDB EntriesNot Available
FDA labelDownload (98.5 KB)
MSDSDownload (74.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5845
P-glycoprotein inhibitor INon-inhibitor0.8631
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8531
CYP450 2C9 substrateNon-substrate0.8799
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5732
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8467
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.8227
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity1.7701 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9394
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Monarch pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hoffmann la roche inc
  • Fsc laboratories inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous
LiquidOphthalmic
SolutionOphthalmic
Solution / dropsOphthalmic
SolutionOral50 mg/5mL
SolutionIntravenous
Injection, solution, concentrateIntravenous
SuspensionOral
TabletOral
TabletOral100 mg/1
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Bactrim ds tablet5.53USD tablet
Bactrim DS 800-160 mg tablet3.0USD tablet
Septra DS 800-160 mg tablet2.43USD tablet
Septra ds tablet2.33USD tablet
Trimethoprim powder1.79USD g
Bactrim 400-80 mg tablet1.63USD tablet
Septra 80-400 tablet1.49USD tablet
Sulfamethoxazole-tmp ds tablet1.44USD tablet
Sulfamethoxazole-tmp vial0.84USD ml
Trimethoprim 100 mg tablet0.7USD tablet
Sulfamethoxazole-Trimethoprim 400-80 mg tablet0.69USD tablet
Apo-Trimethoprim 200 mg Tablet0.55USD tablet
Primsol 50 mg/5 ml oral soln0.39USD ml
Apo-Trimethoprim 100 mg Tablet0.27USD tablet
Sulfamethoxazole-tmp ss tablet0.17USD tablet
Sulfamethoxazole-Trimethoprim 200-40 mg/5ml Suspension0.13USD ml
Sulfatrim 200-40 mg/5ml Suspension0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5763449 No1996-08-072016-08-07Us
US5962461 No1996-08-072016-08-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point199-203 °CPhysProp
water solubility400 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.91HANSCH,C ET AL. (1995)
logS-2.86ADME Research, USCD
pKa7.12 (at 20 °C)PERRIN,DD (1972)
Predicted Properties
PropertyValueSource
Water Solubility0.615 mg/mLALOGPS
logP1.26ALOGPS
logP1.28ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)17.33ChemAxon
pKa (Strongest Basic)7.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.51 m3·mol-1ChemAxon
Polarizability29.71 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Pyrimidine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gamarro F, Yu PL, Zhao J, Edman U, Greene PJ, Santi D: Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme. Mol Biochem Parasitol. 1995 Jun;72(1-2):11-22. [PubMed:8538681 ]
  4. Rosowsky A, Papoulis AT, Forsch RA, Queener SF: Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. J Med Chem. 1999 Mar 25;42(6):1007-17. [PubMed:10090784 ]
  5. Reche P, Arrebola R, Santi DV, Gonzalez-Pacanowska D, Ruiz-Perez LM: Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol. 1996 Feb-Mar;76(1-2):175-85. [PubMed:8920005 ]
  6. Oefner C, Parisi S, Schulz H, Lociuro S, Dale GE: Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):751-7. doi: 10.1107/S0907444909013936. Epub 2009 Jul 10. [PubMed:19622858 ]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Laskowska E, Kuczynska-Wisnik D, Bak M, Lipinska B: Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells. Curr Microbiol. 2003 Oct;47(4):286-9. [PubMed:14629008 ]
  2. Floris-Moore MA, Amodio-Groton MI, Catalano MT: Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother. 2003 Dec;37(12):1810-3. [PubMed:14632594 ]
  3. Rosowsky A, Fu H, Chan DC, Queener SF: Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridine s as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. J Med Chem. 2004 May 6;47(10):2475-85. [PubMed:15115391 ]
  4. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM: Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004 Nov;48(11):4301-5. [PubMed:15504856 ]
  5. Barrow EW, Bourne PC, Barrow WW: Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim. Antimicrob Agents Chemother. 2004 Dec;48(12):4643-9. [PubMed:15561838 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:43